# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Myxoid liposarcoma

Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 1-9 of 9 results.
Dose Reduction of Preoperative Radiotherapy in Myxoid Liposarcomas
Status: Recruiting
Last Changed: Aug 08, 2018
First Received: Apr 08, 2014
Disease(s): Myxoid Liposarcoma of Soft Tissue
Intervention(s): dose reduction of preoperative radiotherapy in MLS
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Harvard Cancer Center, Boston, Massachusetts, United States
University Hospital Aarhus, Aarhus, Denmark
The Netherlands Cancer Institute, Amsterdam, Noord Holland, Netherlands
Academisch Medisch centrum, Amsterdam, Netherlands
... and 8 other locations.
Sirolimus and Cyclophosphamide in Metastatic or Unresectable Myxoid Liposarcoma and Chondrosarcoma
Status: Recruiting
Last Changed: Jul 11, 2018
First Received: Jul 01, 2016
Disease(s): Conventional Chondrosarcoma, Myxoid Liposarcoma, Mesenchymal Chondrosarcoma, Dedifferentiated Chondrosarcoma
Intervention(s): sirolimus and cyclophosphamide
Locations: LUMC, Leiden, Netherlands
Hospital de Sant Pau, Barcelona, Spain
Hospital Val d'Hebron, Barcelona, Spain
CIO Clara Campal, Madrid, Spain
Hospital Universitario Virgen del Rocío, Sevilla, Spain
... and 3 other locations.
A Pilot Study of NY-ESO-1ᶜ²⁵⁹T Cells in Subjects With Advanced Myxoid/ Round Cell Liposarcoma
Status: Recruiting
Last Changed: Oct 16, 2018
First Received: Dec 14, 2016
Disease(s): Neoplasms
Intervention(s): Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T
Locations: GSK Investigational Site, Tampa, Florida, United States
GSK Investigational Site, Ann Arbor, Michigan, United States
GSK Investigational Site, Saint Louis, Missouri, United States
GSK Investigational Site, New York, New York, United States
GSK Investigational Site, Columbus, Ohio, United States
... and 1 other locations.
Study of Adoptive Immunotherapy Using Autologous CD8+ NY-ESO-1-Specific T Cells and the NY-ESO-1 Immunostimulatory Agents LV305 or CMB305 For Patients With Sarcoma
Status: Recruiting
Last Changed: Jan 30, 2019
First Received: Mar 01, 2018
Disease(s): Malignant Neoplasms of Bone and Articular Cartilage, Malignant Neoplasms of Mesothelial and Soft Tissue, Synovial Sarcoma, Myxoid Liposarcoma
Intervention(s): Modified T Cells, Cyclophosphamide, IL-2, LV305, CMB305
Locations: University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Itacitinib in Treating Participants With Refractory Metastatic/Advanced Soft Tissue Sarcomas
Status: Not yet recruiting
Last Changed: Dec 21, 2018
First Received: Sep 13, 2018
Disease(s): Metastatic Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Round Cell Liposarcoma
Intervention(s): Itacitinib, Laboratory Biomarker Analysis
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
Status: Recruiting
Last Changed: Dec 07, 2018
First Received: Jan 16, 2018
Disease(s): Multiple Myeloma, Melanoma, Synovial Sarcoma, Myxoid/Round Cell Liposarcoma
Intervention(s): NY-ESO-1 redirected autologous T cells with CRISPR edited endogenous TCR and PD-1, Cyclophosphamide, Fludarabine, NY-ESO-1 expression testing
Locations: University of Pennsylvania, Philadelphia, Pennsylvania, United States
Pembrolizumab and Interferon Gamma-1b in Treating Patients With Stage IB-IVB Relapsed or Refractory Mycosis Fungoides and Sezary Syndrome
Status: Recruiting
Last Changed: Feb 06, 2019
First Received: Feb 24, 2017
Disease(s): Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Metastatic Synovial Sarcoma, NY-ESO-1 Positive Tumor Cells Present, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7, Unresectable Synovial Sarcoma
Intervention(s): Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab
Locations: Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States
... and 1 other locations.
Hypofractionated Radiotherapy With Sequential Chemotherapy in Primary Unresectable or Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall
Status: Recruiting
Last Changed: Aug 31, 2018
First Received: Aug 29, 2018
Disease(s): Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Myosarcoma, Histiocytic Sarcoma, Synovial Sarcoma, Lymphangiosarcoma, Malignant Peripheral Nerve Sheath Tumors, Myxofibrosarcoma, Myxoid Liposarcoma, Undifferentiated Sarcoma, Pleomorphic Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, Pleomorphic Rhabdomyosarcoma, Malignant Triton Tumor
Intervention(s): Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
Locations: Maria Sklodowska-Curie Institute - Oncology Center, Warsaw, Mazovian, Poland
MAGE-A4ᶜ¹º³²T for Multi-Tumor
Status: Recruiting
Last Changed: Feb 06, 2019
First Received: Apr 28, 2017
Disease(s): Urinary Bladder Cancer, Melanoma, Head and Neck Cancer, Ovarian Cancer, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Synovial Sarcoma, Myxoid Round Cell Liposarcoma
Intervention(s): Autologous genetically modified MAGE-A4ᶜ¹º³²T cells
Locations: University of Miami, Miami, Florida, United States
Washington University School of Medicine, Saint Louis, Missouri, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Tennessee Oncology - Sarah Cannon Research Institute, Nashville, Tennessee, United States
... and 3 other locations.